<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36047371</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1755-5949</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>CNS neuroscience &amp; therapeutics</Title><ISOAbbreviation>CNS Neurosci Ther</ISOAbbreviation></Journal><ArticleTitle>Effect of neurofilament analysis on the diagnostic delay in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>70</StartPage><EndPage>77</EndPage><MedlinePgn>70-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cns.13960</ELocationID><Abstract><AbstractText Label="AIMS">The aim of this study was to investigate whether neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) in cerebrospinal fluid (CSF), sampled prior to referral to a neuromuscular reference center (NMRC), shorten the diagnostic delay in patients with amyotrophic lateral sclerosis.</AbstractText><AbstractText Label="METHODS">In this retrospective study, patients with ALS were included with (i) determination of neurofilaments (Nfs) before referral to the NMRC (preC-Nfs ALS, n&#xa0;=&#x2009;58), (ii) determination of Nfs at the NMRC (C-Nfs, n&#xa0;=&#x2009;54) or (iii) with no determination of Nfs (C-No Nfs, n&#xa0;=&#x2009;180). Fifty-six disease controls were included.</AbstractText><AbstractText Label="RESULTS">The preC-Nfs cohort had CSF sampled 2.2&#xa0;months (range: 0.6-12.0&#xa0;months) before referral to the NMRC. In this cohort, the diagnostic delay was significantly shorter [median (range): 8.24 (2.37-49.7) months] than in the C-Nfs cases [median (range): 11.4 (2.93-86.5) months; p&#xa0;&lt;&#x2009;0.05], but not in the C-No Nfs cases. When including the disease progression rate and the presence of a genetic mutation as covariates, the difference ceased to exist (p&#xa0;=&#x2009;0.14). pNfH and NfL levels in the preC-Nfs cohort were significantly higher than in disease controls (p&#xa0;&lt;&#x2009;0.0001). Both Nfs showed a similar discriminating performance.</AbstractText><AbstractText Label="CONCLUSIONS">CSF Nfs assessed before the diagnosis of ALS at a NMRC decreased the diagnostic delay in specific cases by 3&#xa0;months and only when other covariates were not taken into account.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. CNS Neuroscience &amp; Therapeutics published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Schaepdryver</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2480-863X</Identifier><AffiliationInfo><Affiliation>Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masrori</LastName><ForeName>Pegah</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8247-1866</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Center for Brain &amp; Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Neurology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Center for Brain &amp; Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Neurology, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poesen</LastName><ForeName>Koen</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5290-9476</Identifier><AffiliationInfo><Affiliation>Laboratory for Molecular Neurobiomarker Research, Department of Neurosciences, Leuven Brain Institute, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>CNS Neurosci Ther</MedlineTA><NlmUniqueID>101473265</NlmUniqueID><ISSNLinking>1755-5930</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007382" MajorTopicYN="N">Intermediate Filaments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cerebrospinal fluid</Keyword><Keyword MajorTopicYN="N">diagnostic delay</Keyword><Keyword MajorTopicYN="N">neurofilament</Keyword></KeywordList><CoiStatement>M.D.S. and P.M. have nothing to report. P.V.D. received a grant from CSL Behring&#x2014;E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders. P.V.D. participated in advisory board meetings for Biogen, UCB, Cytokinetics, Ferrer, Alexion Pharmaceuticals, Muna Therapeutics, Alector, Argenx, Augustine Therapeutics, QurAlis. P.V.D received honoraria for lectures/presentations from Biogen. K.P. is supported by a grant of the Research Foundation&#x2014;Flanders (FWO, Fonds voor Wetenschappelijk Onderzoek Flanders, Belgium).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>1</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36047371</ArticleId><ArticleId IdType="pmc">PMC9804063</ArticleId><ArticleId IdType="doi">10.1111/cns.13960</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Shatunov A, Al&#x2010;Chalabi A. The genetic architecture of ALS. Neurobiol Dis. 2021;147:105156. doi:10.1016/j.nbd.2020.105156</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105156</ArticleId><ArticleId IdType="pubmed">33130222</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5&#x2013;6):310&#x2010;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group . Edaravone (MCI&#x2010;186) ALS 19 study group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16(7):505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jongh AD, van Eijk RPA, van den Berg LH. Evidence for a multimodal effect of riluzole in patients with ALS? J Neurol Neurosurg Psychiatry. 2019;90(10):1183&#x2010;1184. doi:10.1136/jnnp-2018-320211</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320211</ArticleId><ArticleId IdType="pubmed">30846539</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey J&#x2010;H, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose&#x2010;ranging study. Lancet Neurol. 2018;4422(18):1&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Kliest T, van den Berg LH. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33(5):655&#x2010;661.</Citation><ArticleIdList><ArticleId IdType="pubmed">32796282</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Lee A, et al. Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):453&#x2010;456. doi:10.3109/21678421.2014.903974</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.903974</ArticleId><ArticleId IdType="pmc">PMC4433003</ArticleId><ArticleId IdType="pubmed">24981792</ArticleId></ArticleIdList></Reference><Reference><Citation>Nzwalo H, de Abreu D, Swash M, Pinto S, de Carvalho M. Delayed diagnosis in ALS: the problem continues. J Neurol Sci. 2014;343(1&#x2013;2):173&#x2010;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">24972820</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin M, Madden C, Maguire S, et al. Patient journey to a specialist amyotrophic lateral sclerosis multidisciplinary clinic: an exploratory study. BMC Health Serv Res. 2015;15:571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690216</ArticleId><ArticleId IdType="pubmed">26700026</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin M, Ryan P, Maguire S, et al. The path to specialist multidisciplinary care in amyotrophic lateral sclerosis: a population&#x2010; based study of consultations, interventions and costs. PLoS One. 2017;12(6):e0179796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5480998</ArticleId><ArticleId IdType="pubmed">28640860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JW, Kang SW, Choi WA. Clinical course of amyotrophic lateral sclerosis according to initial symptoms: an analysis of 500 cases. Yonsei Med J. 2021;62(4):338&#x2010;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007429</ArticleId><ArticleId IdType="pubmed">33779087</ArticleId></ArticleIdList></Reference><Reference><Citation>Cellura E, Spataro R, Taiello AC, La Bella V. Factors affecting the diagnostic delay in amyotrophic lateral sclerosis. Clin Neurol Neurosurg. 2012;114(6):550&#x2010;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">22169158</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta&#x2010;analysis. JAMA Neurol. 2019;76(9):1035&#x2010;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2019;9(1167):1&#x2010;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Gafson AR, Barth&#xe9;lemy NR, Bomont P, et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain. 2020;143(7):1975&#x2010;1998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363489</ArticleId><ArticleId IdType="pubmed">32408345</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88(24):2302&#x2010;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Jeromin A, Gille B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;89(4):367&#x2010;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87(1):12&#x2010;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84(1):130&#x2010;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. Neurofilaments in pre&#x2010;symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7&#x2013;8):538&#x2010;548. doi:10.1080/21678421.2019.1646769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Goossens J, De Meyer S, et al. Serum neurofilament heavy chains as early marker of motor neuron degeneration. Ann Clin Transl Neurol. 2019;6(10):1971&#x2010;1979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6801162</ArticleId><ArticleId IdType="pubmed">31518073</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011;70(1):79&#x2010;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">21437935</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A. How to improve the diagnostic process. J Neurol. 1999;246(Suppl 3):III6&#x2010;III9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10631653</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez&#x2010;Molina M, Argente&#x2010;Escrig H, Polo MF, et al. Early referral to an ALS center reduces several months the diagnostic delay: a multicenter&#x2010;based study. Front Neurol. 2020;11:604922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7775542</ArticleId><ArticleId IdType="pubmed">33391167</ArticleId></ArticleIdList></Reference><Reference><Citation>Matharan M, Mathis S, Bonabaud S, Carla L, Soulages A, Le Masson G. Minimizing the diagnostic delay in amyotrophic lateral sclerosis: the role of nonneurologist practitioners. Neurol Res Int. 2020;2020:1473981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7238340</ArticleId><ArticleId IdType="pubmed">32455015</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbgebauer S, Steinacker P, Verde F, et al. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol Neurosurg Psychiatry. 2021;93(1):68&#x2010;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">34417339</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi A, Pujol&#x2010;Calder&#xf3;n F, Tjust AE, et al. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics. Sci Rep. 2021;11(1):22128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8585882</ArticleId><ArticleId IdType="pubmed">34764380</ArticleId></ArticleIdList></Reference><Reference><Citation>Palese F, Sartori A, Logroscino G, Pisa FE. Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):176&#x2010;185. doi:10.1080/21678421.2018.1550517</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1550517</ArticleId><ArticleId IdType="pubmed">30656971</ArticleId></ArticleIdList></Reference><Reference><Citation>Escal J, Fourier A, Formaglio M, et al. Comparative diagnosis interest of NfL and pNfH in CSF and plasma in a context of FTD&#x2010;ALS spectrum. J Neurol. 2021;269:1522&#x2010;1529. doi:10.1007/s00415-021-10714-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10714-3</ArticleId><ArticleId IdType="pubmed">34313819</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognat E, De Schaepdryver M, Hugon J, Poesen K, Paquet C. Elevated ALS biomarker levels in CSF of a FTD patient at the presymptomatic stage of ALS. Alzheimer Dis Assoc Disord. 2018;32(2):156&#x2010;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">29189300</ArticleId></ArticleIdList></Reference><Reference><Citation>Saracino D, Dorgham K, Camuzat A, et al. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN&#x2010;associated diseases: from tailored references to clinical applications. J Neurol Neurosurg Psychiatry. 2021;92(12):1278&#x2010;1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8606463</ArticleId><ArticleId IdType="pubmed">34349004</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>